MedTrace Logo

A Study in Subjects With Neurogenic Orthostatic Hypotension

NCT07089043 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-05

No results posted yet for this study

Summary

This is a study to evaluate the effects of CST-3056 on orthostatic symptoms and signs in subjects with neurogenic orthostatic hypotension (nOH).

Conditions

  • Neurogenic Orthostatic Hypotension

Interventions

DRUG

CST-3056

Administered as an oral solution

DRUG

Placebo

Administered as an oral solution

Sponsors & Collaborators

  • CuraSen Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · CuraSen Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-12
Primary Completion
2026-05-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07089043 on ClinicalTrials.gov